Bessemer Venture Partners led a $121m Series B round is Seismic Therapeutic.

Bessemer Venture Partners led a $121m Series B round is Seismic Therapeutic,a biotechnology company advancing machine learning for immunology drug development, with participation from Amgen Ventures, Codon Capital, Alexandria Venture Investments, Gaingels and GC&H, Timothy A. Springer, Lightspeed Venture Partners, Polaris Partners, Boxer Capital, GV and Samsara BioCapital. “Seismic has made impressive achievements in a short time integrating the power of machine learning with its deep drug development expertise to create two differentiated lead programs, each offering a compelling opportunity to address unmet medical needs in autoimmune diseases in a new way. We look forward to collaborating with the Seismic team to realize the full potential of its unique approach to immunology drug development, enabled by machine learning,” Andrew Hedin Bessemer Venture Partners Biotech and Healthcare Partner.